Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Anti-IgE in Chronic Urticaria
NCT00130234Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Nov 2004
- Primary completion
- Sep 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in chronic urticaria (CU), sponsored by Johns Hopkins University. Started Nov 2004; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on NCT00130234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00130234.